EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

AI-powered model for accurate prediction of MCI-to-AD progression

Ahmed Abdelhameed, Jingna Feng, Xinyue Hu, Fang Li, Sori Lundin, Paul E Schulz, Cui Tao

Acta Pharmaceutica Sinica B · 2025-09 · 15 (9) · 4427-4437

DOI: 10.1016/j.apsb.2025.01.027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-09. Verfasst von Ahmed Abdelhameed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, FL 32224, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) remains a formidable challenge in modern healthcare, necessitating innovative approaches for its early detection and intervention. This study aimed to enhance the identification of individuals with mild cognitive impairment (MCI) at risk of developing AD. Leveraging advances in computational power and the extensive availability of healthcare data, we explored the potential of deep learning models for early prediction using medical claims data. We employed a bidirectional gated recurrent unit (BiGRU) deep learning model for predictive modeling of MCI progression across various prediction intervals, extending up to five years post-initial MCI diagnosis. The performance of the BiGRU model was rigorously compared with several machine-learning model baselines to evaluate its efficacy. Using a robust cross-validation methodology, the BiGRU emerged as the top-performing model, achieving an Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of 0.833 (95% CI: 0.822, 0.843), an Area Under the Precision-Recall Curve (AUC-PR) of 0.856 (95% CI: 0.845, 0.867), and an F1-Score of 0.71 (95% CI: 0.694, 0.724) for a five-year prediction interval. The results indicate that BiGRU, utilizing longitudinal claims data, reliably predicts MCI-to-AD progression over a lengthy interval following the initial MCI diagnosis, offering clinicians a valuable tool for targeted risk identification and stratification.

Schlagwörter

Stichwörter der Autor:innen

BiGRUElectronic health recordsLongitudinal claim dataMachine learningPredictive modelingRisk stratification

Autor:innen und Institutionen

  • Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, FL 32224, USA.
  • McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Förderung

  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Abdelhameed, A., Feng, J., Hu, X., Li, F., Lundin, S., Schulz, P. E., & Tao, C. (2025). AI-powered model for accurate prediction of MCI-to-AD progression. Acta Pharmaceutica Sinica B, 15(9), 4427-4437. https://doi.org/10.1016/j.apsb.2025.01.027

Vancouver

Abdelhameed A, Feng J, Hu X, Li F, Lundin S, Schulz PE, et al. AI-powered model for accurate prediction of MCI-to-AD progression. Acta Pharmaceutica Sinica B. 2025;15(9):4427-4437. doi:10.1016/j.apsb.2025.01.027

BibTeX
@article{Abdelhameed2025,
  author = {Abdelhameed, Ahmed and Feng, Jingna and Hu, Xinyue and Li, Fang and Lundin, Sori and Schulz, Paul E and Tao, Cui},
  title = {AI-powered model for accurate prediction of MCI-to-AD progression},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {9},
  pages = {4427--4437},
  doi = {10.1016/j.apsb.2025.01.027}
}
Kostenlos starten →